高级检索
    汪阿影, 吕镗烽. 联合免疫，安全可行——评区域MSLN CAR-T细胞联合抗PD-1药物在治疗恶性胸膜疾病患者中的应用[J]. 循证医学, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
    引用本文: 汪阿影, 吕镗烽. 联合免疫，安全可行——评区域MSLN CAR-T细胞联合抗PD-1药物在治疗恶性胸膜疾病患者中的应用[J]. 循证医学, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
    shu
    WANG A-ying, LV Tang-feng. Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab[J]. Journal of Evidence-Based Medicine, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
    Citation: WANG A-ying, LV Tang-feng. Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab[J]. Journal of Evidence-Based Medicine, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
    shu

    联合免疫，安全可行——评区域MSLN CAR-T细胞联合抗PD-1药物在治疗恶性胸膜疾病患者中的应用

    Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab

      摘要
      • HTML全文
      • 参考文献(9)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回